The armamentarium of acute medications for migraine is set to expand further with the results of a phase III trial, in which intranasal administration of zavegepant was superior to placebo in treating a single migraine attack. The therapeutic benefits were modest, however, and so more work is needed to address unmet treatment needs.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Progress in treating migraines: promising prospects for a better tomorrow
Bulletin of the National Research Centre Open Access 21 August 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ashina, M. Migraine. N. Engl. J. Med. 383, 1866–1876 (2020).
Eigenbrodt, A. K. et al. Diagnosis and management of migraine in ten steps. Nat. Rev. Neurol. 17, 501–514 (2021).
Lipton, R. B., Hamelsky, S. W. & Dayno, J. M. What do patients with migraine want from acute migraine treatment? Headache 42 (Suppl. 1), 3–9 (2002).
Ashina, M. et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet 397, 1505–1518 (2021).
Croop, R. et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 397, 51–60 (2021).
Lipton, R. B. et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 22, 209–217 (2023).
Croop, R. et al. Zavegepant nasal spray for the acute treatment of migraine: a phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache 62, 1153–1163 (2022).
Derry, S. & Moore, R. A. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 2013, CD008040 (2013).
Derry, C. J., Derry, S. & Moore, R. A. Sumatriptan (all routes of administration) for acute migraine attacks in adults — overview of Cochrane reviews. Cochrane Database Syst. Rev. 2014, CD009108 (2014).
Bird, S., Derry, S. & Moore, R. A. Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst. Rev. 2014, CD008616 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.A. reports personal fees from Teva, outside of the submitted work. P.T.-H. declares no competing interests.
Rights and permissions
About this article
Cite this article
Ashina, H., Tfelt-Hansen, P. Zavegepant for the acute treatment of migraine: look before leaping. Nat Rev Neurol 19, 329–330 (2023). https://doi.org/10.1038/s41582-023-00803-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-023-00803-4
This article is cited by
-
Progress in treating migraines: promising prospects for a better tomorrow
Bulletin of the National Research Centre (2023)